Arcadia Biosciences (NASDAQ:RKDA) Issues Earnings Results, Misses Estimates By $1.53 EPS

Arcadia Biosciences (NASDAQ:RKDA) issued its quarterly earnings data on Thursday. The basic materials company reported ($2.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($1.53), FiscalAI reports. Arcadia Biosciences had a negative return on equity of 144.61% and a negative net margin of 234.53%.The company had revenue of $1.44 million for the quarter, compared to the consensus estimate of $1.90 million.

Arcadia Biosciences Price Performance

Shares of NASDAQ RKDA traded up $0.05 during midday trading on Friday, hitting $0.62. 139,968 shares of the company’s stock were exchanged, compared to its average volume of 156,549. The stock’s 50 day moving average price is $0.72 and its 200-day moving average price is $1.21. The firm has a market cap of $1.51 million, a P/E ratio of -0.14 and a beta of 0.56. Arcadia Biosciences has a twelve month low of $0.50 and a twelve month high of $6.71.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Arcadia Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Arcadia Biosciences has a consensus rating of “Sell”.

About Arcadia Biosciences

Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.

Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.